FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2497129282> ?p ?o ?g. }

• W2497129282 endingPage "3335" @default.
• W2497129282 startingPage "3327" @default.
• W2497129282 abstract "BACKGROUND Filanesib is a kinesin spindle protein inhibitor that has demonstrated encouraging activity in patients with recurrent/refractory multiple myeloma. Preclinical synergy with bortezomib was the rationale for the current phase 1 study. METHODS The current study was a multicenter study with an initial dose-escalation phase to determine the maximum tolerated dose of 2 schedules of filanesib plus bortezomib with and without dexamethasone, followed by a dose-expansion phase. RESULTS With the addition of prophylactic filgastrim, the maximum planned dose was attained: 1.3 mg/m2/day of bortezomib plus 40 mg of dexamethasone on days 1, 8, and 15 of a 28-day cycle, with filanesib given intravenously either at a dose of 1.5 mg/m2/day (schedule 1: days 1, 2, 15, and 16) or 3 mg/m2/day (schedule 2: days 1 and 15). The most common adverse events (assessed for severity using version 4.0 of the National Cancer Institute Common Terminology Criteria for Adverse Events) were transient, noncumulative neutropenia and thrombocytopenia with grade 3/4 events reported in 44% (16% in cycle 1 with filgastrim) and 29% of patients, respectively. A low (≤11%) overall rate of nonhematological grade 3/4 toxicity was observed. With a median of 3 prior lines of therapy and 56% of patients with disease that was refractory to proteasome inhibitors, the overall response rate was 20% (55 patients), and was 29% in 14 patients with proteasome inhibitors-refractory disease receiving filanesib at a dose of ≥1.25 mg/m2 (duration of response, 5.2 to ≥21.2 months). CONCLUSIONS The current phase 1 study established a dosing schedule for the combination of these agents that demonstrated a favorable safety profile with a low incidence of nonhematologic toxicity and manageable hematologic toxicity. The combination of filanesib, bortezomib, and dexamethasone appears to have durable activity in patients with recurrent/refractory multiple myeloma. Cancer 2016;122:3327–3335. © 2016 American Cancer Society." @default.
• W2497129282 created "2016-08-23" @default.
• W2497129282 creator A5006108161 @default.
• W2497129282 creator A5006298561 @default.
• W2497129282 creator A5020248787 @default.
• W2497129282 creator A5022683984 @default.
• W2497129282 creator A5022766377 @default.
• W2497129282 creator A5023974827 @default.
• W2497129282 creator A5027017988 @default.
• W2497129282 creator A5034791164 @default.
• W2497129282 creator A5049554397 @default.
• W2497129282 creator A5057911528 @default.
• W2497129282 creator A5064538334 @default.
• W2497129282 creator A5076622910 @default.
• W2497129282 creator A5077802087 @default.
• W2497129282 creator A5077897003 @default.
• W2497129282 date "2016-07-19" @default.
• W2497129282 modified "2023-09-26" @default.
• W2497129282 title "A phase 1 dose-escalation study of filanesib plus bortezomib and dexamethasone in patients with recurrent/refractory multiple myeloma" @default.
• W2497129282 cites W1970565466 @default.
• W2497129282 cites W1988265934 @default.
• W2497129282 cites W2013113192 @default.
• W2497129282 cites W2064937772 @default.
• W2497129282 cites W2085073923 @default.
• W2497129282 cites W2095255742 @default.
• W2497129282 cites W2124560610 @default.
• W2497129282 cites W2135491950 @default.
• W2497129282 cites W2139806767 @default.
• W2497129282 cites W2140579395 @default.
• W2497129282 cites W2169183166 @default.
• W2497129282 cites W2527913164 @default.
• W2497129282 cites W2980259995 @default.
• W2497129282 doi "https://doi.org/10.1002/cncr.30174" @default.
• W2497129282 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6857452" @default.
• W2497129282 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27433944" @default.
• W2497129282 hasPublicationYear "2016" @default.
• W2497129282 type Work @default.
• W2497129282 sameAs 2497129282 @default.
• W2497129282 citedByCount "28" @default.
• W2497129282 countsByYear W24971292822017 @default.
• W2497129282 countsByYear W24971292822018 @default.
• W2497129282 countsByYear W24971292822019 @default.
• W2497129282 countsByYear W24971292822020 @default.
• W2497129282 countsByYear W24971292822021 @default.
• W2497129282 countsByYear W24971292822022 @default.
• W2497129282 countsByYear W24971292822023 @default.
• W2497129282 crossrefType "journal-article" @default.
• W2497129282 hasAuthorship W2497129282A5006108161 @default.
• W2497129282 hasAuthorship W2497129282A5006298561 @default.
• W2497129282 hasAuthorship W2497129282A5020248787 @default.
• W2497129282 hasAuthorship W2497129282A5022683984 @default.
• W2497129282 hasAuthorship W2497129282A5022766377 @default.
• W2497129282 hasAuthorship W2497129282A5023974827 @default.
• W2497129282 hasAuthorship W2497129282A5027017988 @default.
• W2497129282 hasAuthorship W2497129282A5034791164 @default.
• W2497129282 hasAuthorship W2497129282A5049554397 @default.
• W2497129282 hasAuthorship W2497129282A5057911528 @default.
• W2497129282 hasAuthorship W2497129282A5064538334 @default.
• W2497129282 hasAuthorship W2497129282A5076622910 @default.
• W2497129282 hasAuthorship W2497129282A5077802087 @default.
• W2497129282 hasAuthorship W2497129282A5077897003 @default.
• W2497129282 hasBestOaLocation W24971292822 @default.
• W2497129282 hasConcept C121332964 @default.
• W2497129282 hasConcept C126322002 @default.
• W2497129282 hasConcept C141071460 @default.
• W2497129282 hasConcept C142424586 @default.
• W2497129282 hasConcept C197934379 @default.
• W2497129282 hasConcept C2776364478 @default.
• W2497129282 hasConcept C2776694085 @default.
• W2497129282 hasConcept C2777063308 @default.
• W2497129282 hasConcept C2777478702 @default.
• W2497129282 hasConcept C2777793932 @default.
• W2497129282 hasConcept C2778822529 @default.
• W2497129282 hasConcept C2780401358 @default.
• W2497129282 hasConcept C29730261 @default.
• W2497129282 hasConcept C31760486 @default.
• W2497129282 hasConcept C71924100 @default.
• W2497129282 hasConcept C87355193 @default.
• W2497129282 hasConcept C90924648 @default.
• W2497129282 hasConceptScore W2497129282C121332964 @default.
• W2497129282 hasConceptScore W2497129282C126322002 @default.
• W2497129282 hasConceptScore W2497129282C141071460 @default.
• W2497129282 hasConceptScore W2497129282C142424586 @default.
• W2497129282 hasConceptScore W2497129282C197934379 @default.
• W2497129282 hasConceptScore W2497129282C2776364478 @default.
• W2497129282 hasConceptScore W2497129282C2776694085 @default.
• W2497129282 hasConceptScore W2497129282C2777063308 @default.
• W2497129282 hasConceptScore W2497129282C2777478702 @default.
• W2497129282 hasConceptScore W2497129282C2777793932 @default.
• W2497129282 hasConceptScore W2497129282C2778822529 @default.
• W2497129282 hasConceptScore W2497129282C2780401358 @default.
• W2497129282 hasConceptScore W2497129282C29730261 @default.
• W2497129282 hasConceptScore W2497129282C31760486 @default.
• W2497129282 hasConceptScore W2497129282C71924100 @default.
• W2497129282 hasConceptScore W2497129282C87355193 @default.
• W2497129282 hasConceptScore W2497129282C90924648 @default.
• W2497129282 hasIssue "21" @default.
• W2497129282 hasLocation W24971292821 @default.

• next